Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Front Oncol

Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.

Published: June 2023

[This corrects the article DOI: 10.3389/fonc.2023.1074793.].

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325674	PMC
http://dx.doi.org/10.3389/fonc.2023.1233247	DOI Listing

Publication Analysis

transarterial chemoembolization

chemoembolization combined

corrigendum transarterial

combined lenvatinib

lenvatinib versus

versus transarterial

combined sorafenib

sorafenib unresectable

unresectable hepatocellular

hepatocellular carcinoma

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!